Search
01/01/2023
Healthcare Professional (HCP) and Patient Usability Evaluation and Preferences of Two Auto-injector Devices for Self-Injection of Biosimilars, SB4 and SB5: A Literature Review
Corominas H., Young D., Cummings J.R.F., Bouhnik Y., Armuzzi A., Thaci D., Kim J.. Healthcare Professional (HCP) and Patient Usability Evaluation and Preferences of Two Auto-injector Devices for Self-Injection of Biosimilars, SB4 and SB5: A Literature Review. CLINICAL DRUG INVESTIGATION. 2023; 43(8)DOI:10.1007/s40261-023-01284-5. PMID:37615857. IF:(Q/D).
01/01/2023
Physical examination today
Casademont J.. Physical examination today. MEDICINA CLINICA. 2023; 160(12)DOI:10.1016/j.medcli.2023.02.001. PMID:36907715. IF:2.600(Q1/3D).
01/01/2023
Immunoglobulins in systemic sclerosis management. A large multicenter experience.
Tandaipan J, Guillén-Del-Castillo A, Simeón-Aznar CP, Carreira PE, De la Puente C, Narváez J, Lluch J, Rubio-Rivas M, Alegre-Sancho JJ, Bonilla G, Moriano C, Casafont-Sole I, García-Vicuña R, Ortiz-Santamaría V, Riera E, Atienza-Mateo B, Blanco R, Galisteo C, Gonzalez-Martin JJ, Pego-Reigosa JM, Pros A, Heredia S, Castellví I. Immunoglobulins in systemic sclerosis management. A large multicenter experience.. AUTOIMMUNITY REVIEWS. 2023; 22(11)DOI:10.1016/j.autrev.2023.103441. PMID:37708984. IF:9.200(Q1/1D).
01/12/2022
Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register
De Miguel, E, Sanchez-Costa, JT, Estrada, P, Munoz, A, Martinez, CV, Alvarado, PM, Garcia-Villanueva, MJ, Angeles, VAN, Da Veiga, CGL, Frutos, AR, Ivorra, JAR, Arrabal, SL, Rocha, MV, Iniguez, CL, Garcia-Gonzalez, M, Molina-Almeda, C, Villar, MA, Mas, AJ, Gonzalez-Gay, MA, Blanco, R. Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register. RMD Open. 2022; 8(2)DOI:10.1136/rmdopen-2022-002507. PMID:36597988. IF:6.200(Q1/2D).
01/12/2022
Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients
Martin-Varillas, JL, Sanchez-Bilbao, L, Calvo-Rio, V, Adan, A, Hernanz, I, Gallego-Flores, A, Beltran-Catalan, E, Castro-Oreiro, S, Fanlo, P, Martos, AG, Torre, I, Cordero-Coma, M, De Dios, JR, Garcia-Aparicio, A, Hernandez-Garfella, M, Sanchez-Andrade, A, Garcia-Valle, A, Maiz, O, Miguelez, R, Rodriguez-Montero, S, Urruticoechea, A, Veroz, R, Conesa, A, Fernandez-Carballido, C, Jovani, V, Mondejar, JJ, Gonzalez, OM, Alvarado, PM, Romero-Yuste, S, Rubio-Munoz, P, Pena-Sainz-Pardo, E, Garijo-Bufort, M, Demetrio-Pablo, R, Hernandez, JL, Blanco, R. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients. RMD Open. 2022; 8(2)DOI:10.1136/rmdopen-2022-002693. PMID:36597972. IF:6.200(Q1/2D).
17/10/2022
Not all autoantibodies are clinically relevant. Classic and novel autoantibodies in Sjogren's syndrome: A critical review
Vilchez-Oya, F, Martin, HB, Garcia-Martinez, E, Corominas, H. Not all autoantibodies are clinically relevant. Classic and novel autoantibodies in Sjogren's syndrome: A critical review. Frontiers in Immunology. 2022; 13DOI:10.3389/fimmu.2022.1003054. PMID:36325321. IF:7.300(Q1/3D).
01/08/2022
Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data
Hemmig, AK, Gozzoli, D, Werlen, L, Ewald, H, Aschwanden, M, Blockmans, D, Brouwer, E, Buchanan, RRC, Camellino, D, Campochiaro, C, Cimmino, MA, Corominas, H, Gloy, V, Henckaerts, L, Kyburz, D, Moya-Alvarado, P, Owen, CE, Stegert, M, Tomelleri, A, van Sleen, Y, Yamashita, H, Imfeld, S, Berger, CT, Hemkens, LG, Daikeler, T. Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data. SEMINARS IN ARTHRITIS AND RHEUMATISM. 2022; 55DOI:10.1016/j.semarthrit.2022.152017. PMID:35537222. IF:5.000(Q2/3D).
01/08/2022
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases
Zozaya N., Arrizubieta Basterrechea M.I., Bollo E., Castellví I., Espín J., Ortego N., Poveda-Andrés J.L., Rodríguez Portal J.A., Rivero A., Marcos-Rodríguez J.A., Verde L.. A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2022; 38(1)DOI:10.1017/S0266462322000459. PMID:35912833. IF:3.200(Q2/5D).
08/07/2022
Continuing medical education. An opportunity to continue improving
Calvo, JIP, Pou, JCI. Continuing medical education. An opportunity to continue improving. MEDICINA CLINICA. 2022; 159(1)DOI:10.1016/j.medcli.2022.03.012. PMID:35636993. IF:3.900(Q2/4D).
01/01/2022
Characteristics associated with the perception of high-impact disease (PsAID =4) in patients with recent-onset psoriatic arthritis. Machine learning-based model
Queiro R., Seoane-Mato D., Laiz A., Agirregoikoa E.G., Montilla C., Park H.-S., Pinto-Tasende J.A., Baute J.J.B., Ibáñez B.J., Toniolo E., Ramírez J., García A.S.. Characteristics associated with the perception of high-impact disease (PsAID =4) in patients with recent-onset psoriatic arthritis. Machine learning-based model. SEMINARS IN ARTHRITIS AND RHEUMATISM. 2022; 57DOI:10.1016/j.semarthrit.2022.152097. PMID:36113222. IF:5.000(Q2/3D).
01/01/2022
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis
Kerick M., Acosta-Herrera M., Simeón-Aznar C.P., Callejas J.L., Assassi S., Carreira P., Castellvi I., Ríos R., Portales R.G., Fernández-Nebro A., García-Hernández F.J., Aguirre M.A., Fernández-Gutiérrez B., Rodríguez-Rodríguez L., de la Peña P.G., Vicente E., Andreu J.L., de Castro M.F., López-Longo F.J., Fonollosa V., Guillén A., Tolosa C., Pros A., Beltrán E., Carballeira M.R., Narváez F.J., Rivas M.R., Ortiz-Santamaría V., Madroñero A.B., González-Gay M.A., Díaz B., Trapiella L., Egurbide M.V., Fanlo-Mateo P., Saez-Comet L., Díaz F., Roman-Ivorra J.A., Sancho J.J.A., Freire M., Garcia F.J.B., Oreiro N., Kreuter A., Riemekasten G., Airò P., Magro C., Voskuyl A.E., Vonk M.C., Hesselstrand R., Nordin A., Lunardi C., Gabrielli A., Hoffmann-Vold A., Distler J.H.W., Padyukov L., Koeleman B.P.C., Proudman S.M., Nikpour M., Stevens W., Zochling J., Sahhar J., Roddy J., Nash P., Tymms K., Rischmueller M., Lester S., Vigone B., Pers J.-O., Saraux A., Devauchelle-Pensec V., Cornec D., Jousse-Joulin S., Lauwerys B., Ducreux J., Maudoux A.-L., Vasconcelos C., Tavares A., Neves E., Faria R., Brandão M., Campar A., Marinho A., Farinha F., Almeida I., Mantecón M.A.G.-G., Alonso R.B., Martínez A.C., Cervera R., Rodríguez-Pintó I., Espinosa G., Lories R., De Langhe E., Belz D., Witte T., Baerlecken N., Stummvoll G., Zauner M., Lehner M., Collantes E., Ortega-Castro R., Aguirre-Zamorano M.A., Escudero-Contreras A., Castro-Villegas M.C., Roldán M.C.F., Ortego N., Raya E., Moleón I.J., de Ramon E., Quintero I.D., Meroni P.L., Gerosa M., Schioppo T., Artusi C., Chizzolini C., Zuber A., Wynar D., Kovács L., Balog A., Deák M., Bocskai M., Dulic S., Kádár G., Hiepe F., Gerl V., Thiel S., Maresca M.R., López-Berrio A., Aguilar-Quesada R., Navarro-Linares H., Hunzelmann N., Moroncini G., de Vries-Bouwstra J.K., Orozco G., Barton A., Herrick A.L., Terao C., Allanore Y., Fonseca C., Alarcón-Riquelme M.E., Radstake T.R.D.J., Beretta L., Denton C.P., Mayes M.D., Martin J.. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis. npj Genomic Medicine. 2022; 7(1)DOI:10.1038/s41525-022-00327-8. PMID:36198672. IF:5.300(Q1/2D).
01/01/2022
Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning
Queiro R., Seoane-Mato D., Laiz A., Agirregoikoa E.G., Montilla C., Park H.-S., Pinto-Tasende J.A., Bethencourt Baute J.J., Ibáñez B.J., Toniolo E., Ramírez J., García A.S., Cañete J.D., Juanola X., Fiter J., Gratacós J., Rodriguez-Moreno J., Rosa J.N., Martín A.L., García A.B., Segura P.C., Ferrer A.L., Barrio S.P., Plata Izquierdo A.J., Bustabad S., Guimerá Martín-Neda F.J., Capdevilla E.F., Díaz R.R., Cuervo A., Gibert M.A., Larraz P.T., de la Morena Barrio I., Lanza L.P., Sanchís D.B., Mesquida C.M., Murillo C., Moreno Ramos M.J., Beteta M.D., Guillén P.S.-P., Oliveira L.L., Marco T.N., Cebrián L., de la Cueva Dobao P., Steiner M., Muñoz-Fernández S., Garrido R.V., León M., Rubio E., Jiménez A.M., Fernández-Freire L.R., Luezas J.M., Sánchez-González M.D., Muñoz C.S., Senabre J.M., Rosas J.C., Soler G.S., Mataix Díaz F.J., Nieto-González J.C., González C., Ovalles Bonilla J.G., Rodríguez O.B., Medina F.J.N., Luján D., Ruiz Montesino M.D., Carrizosa Esquivel A.M., Fernández-Carballido C., Martínez-Vidal M.P., Fernández L.G., Jovani V., Alameda R.C., Sabater S.G., Romero I.B., Urruticoechea-Arana A., Torres M.S., Almodóvar R., López Estebaranz J.L., López Montilla M.D., García-Nieto A.V.. Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning. ARTHRITIS RESEARCH & THERAPY. 2022; 24(1)DOI:10.1186/s13075-022-02838-2. PMID:35751091. IF:4.900(Q2/4D).
01/01/2022
Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
Kuster S., Jordan S., Elhai M., Held U., Steigmiller K., Bruni C., Cacciapaglia F., Vettori S., Siegert E., Rednic S., Codullo V., Airo P., Braun-Moscovici Y., Hunzelmann N., Joao Salvador M., Riccieri V., Gheorghiu A.-M., Alegre Sancho J.J., Romanowska-Prochnicka K., Castellví I., Kötter I., Truchetet M.-E., López-Longo F.J., Novikov P.I., Giollo A., Shirai Y., Belloli L., Zanatta E., Hachulla E., Smith V., Denton C., Ionescu R.M., Schmeiser T., Distler J.H.W., Gabrielli A., Hoffmann-Vold A.-M., Kuwana M., Allanore Y., Distler O.. Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD Open. 2022; 8(2)DOI:10.1136/rmdopen-2022-002477. PMID:36328401. IF:6.200(Q1/2D).
01/01/2022
How do Spanish Rheumatologists handle remission? Survey of knowledge and approach before and after a training workshop
Balsa A., González-Álvaro I., Sanmartí R., Corominas H.. How do Spanish Rheumatologists handle remission? Survey of knowledge and approach before and after a training workshop. Reumatologia Clinica. 2022; 18(9)DOI:10.1016/j.reuma.2021.08.002. PMID:34489191. IF:(Q/D).
01/01/2022
SER-SEPAR recommendations for the the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment
Narváez J., Díaz del Campo Fontecha P., Brito García N., Bonilla G., Aburto M., Castellví I., Cano-Jiménez E., Mena-Vázquez N., Nieto M.A., Ortiz A.M., Valenzuela C., Abad Hernández M.Á., Castrejón I., Correyero Plaza M., Francisco Hernández F.M., Hernández Hernández M.V., Rodríquez Portal J.A.. SER-SEPAR recommendations for the the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment. Reumatologia Clinica. 2022; 18(9)DOI:10.1016/j.reuma.2022.03.005. PMID:36064885. IF:(Q/D).
01/01/2022
SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 1: Epidemiology, risk factors and prognosis
Rodríguez Portal J.A., Brito García N., Díaz del Campo Fontecha P., Valenzuela C., Ortiz A.M., Nieto M.A., Mena-Vázquez N., Cano-Jiménez E., Castellví I., Aburto M., Bonilla G., Hernández Hernández M.V., Hernández F.M.F., Correyero Plaza M., Castrejón I., Abad Hernández M.Á., Narváez J.. SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 1: Epidemiology, risk factors and prognosis. Reumatologia Clinica. 2022; 18(8)DOI:10.1016/j.reuma.2022.02.009. PMID:36085196. IF:(Q/D).
01/01/2022
Correction to: Real-world Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis patients in Spain: Results of a multicenter, observational study in routine clinical practice (The ORBIT-RA Study) (Rheumatology and Therapy, (2022), 9, 2, (589-608), 10.1007/s40744-021-00423-8)
Hernández-Cruz B., Rosas J., Díaz-Torné C., Belzunegui J., García-Vicuña R., Inciarte-Mundo J., Pons A., Millán A.M., Jeria-Navarro S., Valero J.A., García-Castañeda N., Valero C., Llorente I., Calvo A., Díaz-Cerezo S., Núñez M.. Correction to: Real-world Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis patients in Spain: Results of a multicenter, observational study in routine clinical practice (The ORBIT-RA Study) (Rheumatology and Therapy, (2022), 9, 2, (589-608), 10.1007/s40744-021-00423-8). Rheumatology and Therapy. 2022; 9(4)DOI:10.1007/s40744-022-00463-8. PMID:35653064. IF:3.800(Q3/6D).
01/01/2022
Myo-Spain: Spanish Registry of Patients with Idiopathic Inflammatory Myopathy. Methodology
Cobo-Ibáñez T., Sánchez-Piedra C., Nuño-Nuño L., Castellví I., Carrión-Barberà I., Romero-Bueno F., Narváez J., Trallero-Araguás E., Tomero E., Ruiz-Lucea M.E., Larena C., Carrasco Cubero C., Jovaní V., Barbadillo C., Sivera F., Belzunegui J., Pérez Gómez A., Gómez Gómez A., Delgado-Frías E., Pego-Reigosa J.M., Joven B., Ibáñez M., Martínez-González O., Ruiz-Román A., Camins J., Ortega-Castro R., Trenor Larra P., Rodríguez López M., Freire M., Alcocer P., Holgado S., Rúa-Figueroa I., Lozano N., Martínez-Barrio J.. Myo-Spain: Spanish Registry of Patients with Idiopathic Inflammatory Myopathy. Methodology. Reumatologia Clinica. 2022; 18(5)DOI:10.1016/j.reuma.2021.01.007. PMID:33867271. IF:(Q/D).
01/01/2022
Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning
Queiro R., Seoane-Mato D., Laiz A., Galindez Agirregoikoa E., Montilla C., Park H.S., Pinto Tasende J.A., Bethencourt Baute J.J., Joven Ibáñez B., Toniolo E., Ramírez J., Pruenza García-Hinojosa C.. Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning. Frontiers in Medicine. 2022; 9DOI:10.3389/fmed.2022.891863. PMID:35572968. IF:3.900(Q2/4D).
01/01/2022
Recomendaciones para el diagnóstico y tratamiento de la baja masa ósea para la edad cronológica y la osteoporosis infantil en Atención Primaria
Mir-Perelló C., López B.M., Pérez B.S., Torrent R.B., Fernández M.I.G., Corbeto M.L., Gil J.G., Zavala R.G.. Recomendaciones para el diagnóstico y tratamiento de la baja masa ósea para la edad cronológica y la osteoporosis infantil en Atención Primaria. Pediatria De Atencion Primaria. 2022; 24(94)DOI:. PMID:. IF:(Q/D).